Insight Inv LLC Sells 16,645 Shares of Johnson & Johnson $JNJ

Key Points

• Insight Inv LLC reduced its holdings in Johnson & Johnson shares by 60.4%, selling 16,645 shares and owning 10,899 shares worth $1,665,000 after the sale.
• Executive VP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson for over $10 million, decreasing her position by 24.08%.
• Johnson & Johnson recently declared a quarterly dividend of $1.30 per share, with an annualized yield of 2.7% and a payout ratio of 55.61%.

Insight Inv LLC lessened its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 60.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,899 shares of the company's stock after selling 16,645 shares during the period. Insight Inv LLC's holdings in Johnson & Johnson were worth $1,665,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Highline Wealth Partners LLC increased its holdings in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after buying an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson in the 1st quarter worth $47,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson in the 1st quarter worth $48,000. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson in the 1st quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson in the 1st quarter worth $52,000. Institutional investors own 69.55% of the company's stock.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company's stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.16% of the stock is owned by insiders.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $190.66 on Friday. The stock has a market capitalization of $459.16 billion, a price-to-earnings ratio of 20.39, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company has a fifty day moving average of $178.48 and a 200-day moving average of $163.76. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $192.10.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Weiss Ratings raised shares of Johnson & Johnson from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday. Wells Fargo & Company set a $212.00 price target on shares of Johnson & Johnson and gave the stock an "overweight" rating in a report on Friday, October 3rd. HSBC upped their price objective on shares of Johnson & Johnson from $188.00 to $210.00 in a research note on Tuesday, September 30th. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $176.00 to $178.00 and gave the company an "equal weight" rating in a research note on Friday. Finally, UBS Group set a $198.00 price objective on shares of Johnson & Johnson in a research note on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus target price of $192.94.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.